Johan Luthman
Tracked across 8 events · 51 articles · First seen Apr 13, 2026 · Last active Aug 25, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Johan Luthman, EVP and Head of Research & Development at Lundbeck, provided commentary on the promising Phase II data for asedebart, highlighting its potential as a novel therapeutic approach.
Jun 14, 2026 · 6 articles
Tech
Impact: Johan Luthman, EVP and Head of Research & Development at Lundbeck, commented on the progress in neuroscience and Lundbeck's approach to drug development.
Apr 13, 2026 · 6 articles
Business
Impact: Johan Luthman, EVP and Head of Research and Development at Lundbeck, expressed satisfaction with the orphan drug designation, highlighting the company's commitment to rare diseases.
May 18, 2026 · 7 articles
Business
Impact: Johan Luthman, EVP and Head of Research and Development at Lundbeck, commented on the significance of the approval for migraine patients in South Korea.
May 26, 2026 · 7 articles
Regulatory
Impact: Johan Luthman, Lundbeck's EVP R&D, commented on the Fast Track designation as an important milestone for the company's narcolepsy program.
Jul 23, 2026 · 6 articles
Business
Impact: Retiring after seven years, transition of R&D leadership.
Jul 20, 2026 · 7 articles
Regulatory
On August 24, 2026, the International — European Commission granted orphan designation to Lundbeck's investigational anti-ACTH monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing's syndrome of endogenous origin. This designation supports development of…
Impact: Johan Luthman, as Executive Vice President of R&D at Lundbeck, commented on the designation, highlighting its importance and the company's innovation pipeline. His role is primarily communicative in this event.
Aug 24, 2026 · 6 articles
Business
Impact: Lundbeck's R&D head, announced the milestone and expressed confidence in the program.
Jul 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Johan Luthman live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard